Dr. Schreeder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 Cci Dr Nw
Huntsville, AL 35805Phone+1 256-705-4224Fax+1 256-705-4135
Education & Training
Emory University School of MedicineResidency, Internal Medicine, 1973 - 1976
Tulane University School of MedicineClass of 1973
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology
Certifications & Licensure
AZ State Medical License 1978 - Present
AL State Medical License 1979 - 2025
TN State Medical License 1990 - 1996
GA State Medical License 1975 - 1977
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Protocol for Radiofrequency Ablation of Pulmonary Neoplasms Start of enrollment: 2003 Jun 01
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Publications & Presentations
PubMed
- 29 citationsUblituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster
The Lancet. Haematology. 2021-04-01 - 66 citationsUblituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaMatthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Nathan Fowler, Jan A. Burger
Blood. 2019-11-21 - 44 citationsPhase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S. Wang, Erika Hamilton, John Sarantopoulos, John Nemunaitis
Clinical Cancer Research. 2019-06-15
Press Mentions
OneOncology Partners With Huntsville's Clearview Cancer InstituteJanuary 17th, 2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
